Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis YoY Growth in the U.S.: 49.0% in FY2025, down 39.0 pts from a year earlier.
Latest, FY2025
49.0%
Period ended Dec 31, 2025
Change on a year earlier
-39.0 pts
88.0% in FY2024
History
2 years
Since FY2024
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| Leqvio | Cardiovascular, renal and metabolic | Atherosclerotic cardiovascular disease (ASCVD) | 575 | 49 | 623 | 69 | 65 | 1 198 | 59 | 57”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | YoY Growth in the U.S. (% USD / cc) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.0% | -39.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 88.0% | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
Cite this data
StockData. (2026). Novartis YoY Growth in the U.S. (%), annual FY2024–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-leqvio-us-yoy-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.